Buyang Huanwutang Treats Diabetic Peripheral Neuropathy via Mitochondrial Transport in Rats

TIAN Jiaxin; AN Jingwen; ZHANG Tianya; ZHANG Zhihong; ZHANG Wang; SONG Linchun; DUAN Tianmeng; BEN Ying

doi:10.13422/j.cnki.syfjx.20230439

您当前的位置：

首页 >

文章列表页 >

Buyang Huanwutang Treats Diabetic Peripheral Neuropathy via Mitochondrial Transport in Rats

更新时间：2023-06-02

- Buyang Huanwutang Treats Diabetic Peripheral Neuropathy via Mitochondrial Transport in Rats
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 13, Pages: 27-36(2023)
- 作者机构：
  
  河北中医学院中西医结合学院，河北省中西医结合肝肾病证重点实验室，石家庄 050091
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20230439
  CLC： R2-0;R33;R289;R587.1
- Published：05 July 2023，
  
  Published Online：16 March 2023，
  
  Received：08 December 2022，
- 稿件说明：
扫描看全文
田佳鑫,安静文,张天雅等.补阳还五汤对糖尿病大鼠周围神经线粒体运输的作用[J].中国实验方剂学杂志,2023,29(13):27-36.

TIAN Jiaxin,AN Jingwen,ZHANG Tianya,et al.Buyang Huanwutang Treats Diabetic Peripheral Neuropathy via Mitochondrial Transport in Rats[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(13):27-36.
田佳鑫,安静文,张天雅等.补阳还五汤对糖尿病大鼠周围神经线粒体运输的作用[J].中国实验方剂学杂志,2023,29(13):27-36. DOI： 10.13422/j.cnki.syfjx.20230439.

TIAN Jiaxin,AN Jingwen,ZHANG Tianya,et al.Buyang Huanwutang Treats Diabetic Peripheral Neuropathy via Mitochondrial Transport in Rats[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(13):27-36. DOI： 10.13422/j.cnki.syfjx.20230439.

摘要

目的

基于线粒体运输探讨补阳还五汤对糖尿病周围神经病变（DPN）的防治作用机制。

方法

SD大鼠用高糖高脂饲料联合腹腔注射链脲佐菌素（STZ）诱导糖尿病。45只糖尿病大鼠随机分为DPN组、

-硫辛酸组、补阳还五汤组，每组15只，另设15只标准喂养大鼠为正常组。

-硫辛酸组、补阳还五汤组分别给与

-硫辛酸60 mg·kg

-1

·d

-1

、补阳还五汤15 g·kg

-1

·d

-1

灌胃治疗12周。给药结束后检测机械性痛阈（PWT）和运动神经传导速度（MNCV），取双侧坐骨神经及双侧L4-5的背根神经节。用50 mmol·L

-1

葡萄糖和250 μmol·L

-1

棕榈酸钠干预NSC34细胞建立细胞损伤模型，随机分为空白组（10%空白血清）、DPN组（10%空白血清）、

-硫辛酸组（10%

-硫辛酸含药血清）、补阳还五汤组（10%补阳还五汤含药血清）、补阳还五汤加Compound C（CC）组（10%补阳还五汤含药血清+10 μmol·L

-1

CC），分别干预24 h。免疫荧光法、免疫组化法和蛋白免疫印迹法（Western blot）分别检测各实验组磷酸化单磷酸腺苷活化蛋白激酶（p-AMPK）、磷酸化环磷腺苷效应元件结合蛋白（p-CREB）及线粒体运输蛋白驱动家族蛋白成员5A（KIF5A）、细胞质动力蛋白1中间链2（DYNC1I2）的表达。

结果

动物实验中，与正常组比较，DPN组大鼠空腹血糖显著升高（

0.01），MNCV、PWT均显著降低（

0.01）；KIF5A、p-AMPK/AMPK、p-CREB/CREB显著降低（

0.01），DYNC1I2表达显著升高（

0.01）。与DPN组比较，

-硫辛酸组及补阳还五汤组大鼠MNCV、PWT显著升高（

0.01）；KIF5A、p-AMPK/AMPK、p-CREB/CREB明显升高（

0.05，

0.01）；DYNC1I2明显降低（

0.05，

0.01）。与

-硫辛酸组比较，补阳还五汤组MNCV、KIF5A表达明显升高（

0.05），DYNC1I2表达显著降低（

0.01）。细胞实验中，与空白组比较，DPN组KIF5A、p-AMPK/AMPK、p-CREB/CREB显著降低（

0.01），DYNC1I2表达显著升高（

0.01）。与DPN组比较，

-硫辛酸组及补阳还五汤组KIF5A、p-AMPK/AMPK、p-CREB/CREB明显升高（

0.05，

0.01），DYNC1I2显著降低（

0.01）。与

-硫辛酸组比较，补阳还五汤组KIF5A表达明显升高（

0.05）。与补阳还五汤组比较，补阳还五汤加CC组KIF5A、DYNC1I2、p-AMPK/AMPK、p-CREB/CREB显著降低（

0.01）。

结论

补阳还五汤可能通过AMPK/CREB通路调节线粒体顺行运输，发挥神经保护作用，从而防治DPN。

Abstract

Objective

To investigate the mechanism of Buyang Huanwutang in treating diabetic peripheral neuropathy （DPN） via mitochondrial transport.

Method

Diabetes in SD rats was induced by a high-carbohydrate/high-fat diet and intraperitoneal injection of streptozotocin （STZ）. The 45 diabetic rats were randomly assigned into a DPN group， an alpha-lipoic acid （60 mg·kg

-1

·d

-1

） group， and a Buyang Huanwutang （15 g·kg

-1

·d

-1

） group， with 15 rats in each group. Fifteen normal SD rats were fed with the standard diet and set as the control group. The rats were administrated with corresponding drugs

by gavage for 12 weeks. The paw withdraw threshold （PWT） and motor nerve conduction velocity （MNCV） were measured at the end of medication， and the sciatic nerve and the bilateral dorsal root ganglia of L4-5 were collected. The injury model of NSC34 cells was established by treating with 50 mmol·L

-1

glucose and 250 μmol·L

-1

sodium palmitate. The NSC34 cells were then randomly assigned into a blank （10% blank serum） group， a DPN （10% blank serum） group， an apha-lipoic acid （10% apha-lipoic acid-containing serum） group， a Buyang Huanwutang （10% Buyang Huanwutang-containing serum） group， and a Buyang Huanwutang + Compound C （CC）（10% Buyang Huanwutang-containing serum

10 μmol·L

-1

CC） group. The cell intervention lasted for 24 h. The immunofluorescence method， immunohistochemistry， and Western blot were employed to determine the expression levels of phosphorylated adenosine monophosphate-activated protein kinase （p-AMPK）， phosphorylated cAMP-response element binding protein （p-CREB）， kinesin family member 5A （KIF5A）， and dynein cytoplasmic 1 intermediate chain 2 （DYNC1I2）.

Result

Compared with the control group， the DPN group of rats showed increased fasting blood glucose （

0.01）， decreased MNCV and PWT （

0.01）， down-regulated expression of KIF5A， p-AMPK/AMPK， and p-CREB/CREB （

0.01）， and up-regulated expression of DYNC1I2 （

0.01）. Compared with the DPN group， drug intervention groups showed increased MNCV and PWT （

0.01）， up-regulated expression of KIF5A， p-AMPK/AMPK， and p-CREB/CREB （

0.05，

0.01）， and down-regulated expression of DYNC1I2 （

0.05，

0.01）. The Buyang Huanwutang group had higher levels of MNCV and KIF5A （

0.05） and lower level of DYNC1I2 （

0.01） than the apha-lipoic acid group. Compared with the blank group， the DPN group of NSC34 cells showed decreased levels of KIF5A， p-AMPK/AMPK， and p-CREB/CREB （

0.01） and increased level of DYNC1I2 （

0.01）. The apha-lipoic acid group and Buyang Huanwutang group had higher levels of KIF5A， p-AMPK/AMPK， and p-CREB/CREB （

0.05，

0.01） and lower level of DYNC1I2 （

0.01） in NSC34 cells than the DPN group. Buyang Huanwutang group had higher KIF5A level （

0.05） in NSC34 cells than the apha-lipoic acid group. Moreover， the Buyang Huanwutang + CC group had lower levels of KIF5A， DYNC1I2， p-AMPK/AMPK， and p-CREB/CREB （

0.01） in NSC34 cells than the Buyang Huanwutang group.

Conclusion

Buyang Huanwutang may regulate mitochondrial anterograde transport via the AMPK/CREB pathway to prevent and treat DPN.

关键词

糖尿病周围神经病变补阳还五汤线粒体运输单磷酸腺苷活化蛋白激酶（AMPK）/环磷腺苷效应元件结合蛋白（CREB）通路

Keywords

diabetic peripheral neuropathyBuyang Huanwutangmitochondrial transportadenosine monophosphate-activated protein kinase （AMPK）/cAMP-response element binding protein （CREB） pathway

references

张玲霞.2型糖尿病患者周围神经病变相关危险因素分析［J］.交通医学，2021，35（4）：368-369.

MEYER-HAMME G，FRIEDEMANN T，GRETEN J，et al.Electrophysiologically verified effects of acupuncture on diabetic peripheral neuropathy in type 2 diabetes： The randomized， partially double-blinded， controlled ACUDIN trial［J］.J Diabetes，2021，13（6）：469-481.

ZHEREBITSKAYA E，AKUDE E，SMITH D R，et al.Development of selective axonopathy in adult sensory neurons isolated from diabetic rats：Role of glucose-induced oxidative stress［J］.Diabetes，2009，58（6）：1356-1364.

CALLAGHAN B C，LITTLE A A，FELDMAN E L，et al.Enhanced glucose control for preventing and treating diabetic neuropathy［J］.Cochrane Database Syst Rev，2012，6（6）：CD007543.

YU S B，PEKKURNAZ G.Mechanisms orchestrating mitochondrial dynamics for energy homeostasis［J］.J Mol Biol，2018，430（21）：3922-3941.

邓平，陈梦妍，谢佳，等.驱动蛋白家族成员5A介导的溶酶体功能在镉神经毒性中的作用［J］.第三军医大学学报，2022，44（4）：320-328.

RUMORA A E，SAVELIEFF M G，SAKOWSKI S A，et al.Disorders of mitochondrial dynamics in peripheral neuropathy：Clues from hereditary neuropathy and diabetes［J］.Int Rev Neurobiol，2019，145：127-176.

罗雅琴，于新阳，张月明，等.基于AMPK/mTOR/ULK1信号通路介导的自噬探讨芪黄益气摄血方治疗免疫性血小板减少症模型小鼠的作用机制［J］.中国实验方剂学杂志，2022，28（17）：43-51.

冯圣钰，杨华，邹冉，等. 中医治疗糖尿病周围神经病变的研究进展［J］.世界临床药物， 2021，doi：10.3969/j.issn.1003-8914.2010.04.121http://dx.doi.org/10.3969/j.issn.1003-8914.2010.04.121.

张浩.中医药治疗糖尿病周围神经病变的用药规律分析［J］.亚太传统医药，2010，6（7）：151-152.

肖洪彬，刘立萍，李然.补阳还五汤现代研究进展与临床应用［J］.中医药信息，2005，22（6）：52-54.

孙伯欣，李羚青.补阳还五汤治疗糖尿病周围神经病变的临床疗效观察［J］.基因组学与应用生物学，2017，36（8）：3398-3402.

孙洪宽，田园.补阳还五汤加味治疗糖尿病周围神经病变临床观察［J］.北京中医药，2009，28（7）：541-542，565.

张振国，邱作成，马晖，等.补阳还五汤治疗糖尿病周围神经病变30例临床观察［J］.时珍国医国药，2012，23（9）：2353-2354.

COPPEY L，DAVIDSON E，SHEVALYE H，et al.Progressive loss of corneal nerve fibers and sensitivity in rats modeling obesity and type 2 diabetes is reversible with omega-3 fatty acid intervention： Supporting cornea analyses as a marker for peripheral neuropathy and treatment［J］.Diabetes Metab Syndr Obes，2020，13：1367-1384.

贲莹，张天雅，田佳鑫，等.基于SIRT1/p53介导的细胞凋亡途径探讨补阳还五汤对糖尿病周围神经病变的治疗作用及方中黄芪用量［J］.中国实验方剂学杂志，2022，28（2）：1-10.

TESFAYE S，VILEIKYTE L，RAYMAN G，et al.Painful diabetic peripheral neuropathy：Consensus recommendations on diagnosis， assessment and management［J］.Diabetes Metab Res Rev，2011，27（7）：629-638.

JURANEK J K，GEDDIS M S，ROSARIO R，et al.Impaired slow axonal transport in diabetic peripheral nerve is independent of RAGE［J］.Eur J Neurosci，2013，38（8）：3159-3168.

SHARMA R，BURAS E，TERASHIMA T，et al.Hyperglycemia induces oxidative stress and impairs axonal transport rates in mice［J］.PLoS One，2010，5（10）：e13463.

郑艳榕. 轴突线粒体回运促进的神经元线粒体自噬在缺血性神经损伤中的保护作用研究［D］.杭州：浙江大学， 2019.

COURSE M M， WANG X. Transporting mitochondria in neurons ［J］. F1000Res， 2016， 5： 1735.

LEWIS T L， TURI G F， KWON S K， et al. Progressive decrease of mitochondrial motility during maturation of cortical axons in vitro and in vivo ［J］. Curr Biol， 2016， 26（19）： 2602-2608.

KAWAGUCHI K.Role of kinesin-1 in the pathogenesis of SPG10， a rare form of hereditary spastic paraplegia［J］.Neuroscientist，2013，19（4）：336-344.

WANG L，BROWN A.A hereditary spastic paraplegia mutation in kinesin-1A/KIF5A disrupts neurofilament transport［J］.Mol Neurodegener，2010，5：52.

LARSEN J R，SIDENIUS P.Slow axonal transport of structural polypeptides in rat， early changes in streptozocin diabetes， and effect of insulin treatment［J］.J Neurochem，1989，52（2）：390-401.

MEDORI R，JENICH H，AUTILIO-GAMBETTI L，et al.Experimental diabetic neuropathy：Similar changes of slow axonal transport and axonal size in different animal models［J］.J Neurosci，1988，8（5）：1814-1821.

KARLE K N，MÖCKEL D，REID E，et al.Axonal transport deficit in a KIF5A-/- mouse model［J］.Neurogenetics，2012，13（2）：169-179.

CARTONI R，NORSWORTHY M W，BEI F，et al.The mammalian-specific protein armcx1 regulates mitochondrial transport during axon regeneration［J］.Neuron，2017，94（3）：689.

CRACKOWER M A，SINASAC D S，XIA J，et al.Cloning and characterization of two cytoplasmic dynein intermediate chain genes in mouse and human［J］.Genomics，1999，55（3）：257-267.

SHENG Z H.The interplay of axonal energy homeostasis and mitochondrial trafficking and anchoring［J］.Trends Cell Biol，2017，27（6）：403-416.

THOMSON D M，HERWAY S T，FILLMORE N，et al.AMP-activated protein kinase phosphorylates transcription factors of the CREB family［J］.J Appl Physiol （1985），2008，104（2）：429-438.

AMATO S，LIU X，ZHENG B，et al.AMP-activated protein kinase regulates neuronal polarization by interfering with PI3-kinase localization［J］.Science，2011，332（6026）：247-251.

PUTHANVEETTIL S V，MONJE F J，MINIACI M C，et al.A new component in synaptic plasticity： upregulation of kinesin in the neurons of the gill-withdrawal reflex［J］.Cell，2008，135（5）：960-973.

TAO K，MATSUKI N，KOYAMA R.AMP-activated protein kinase mediates activity-dependent axon branching by recruiting mitochondria to axon［J］.Dev Neurobiol，2014，74（6）：557-573.

PATHAK D，BERTHET A，NAKAMURA K.Energy failure：Does it contribute to neurodegeneration？［J］.Ann Neurol，2013，74（4）：506-516.

VINGTDEUX V，DAVIES P，DICKSON D W，et al.AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies［J］.Acta Neuropathol，2011，121（3）：337-349.

周岚.补阳还五汤促进周围神经损伤修复的药理研究［J］.河南中医，2016，36（4）：735-738.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Buyang Huanwutang in Treating Diabetic Peripheral Neuropathy by Inhibiting Pyroptosis Through AMPK/ULK1 Mitophagy Pathway

Therapeutic Effect of Buyang Huanwutang on Diabetic Peripheral Neuropathy Rats from Perspective of Oxidative Stress

Therapeutic Effect of Buyang Huanwutang on Diabetic Peripheral Neuropathy and Dosage of Astragalus in Prescription： Based on SIRT1/p53-mediated Apoptosis

Related Author

AN Jingwen

SONG Linchun

CHEN Die

ZHANG Wang

TIAN Jiaxin

ZHANG Tianya

BEN Ying

Tianya ZHANG

Related Institution

College of Integrated Traditional Chinese and Western Medicine，Hebei University of Chinese Medicine，Hebei Key Laboratory of Integrated Medicine on Liver-kidney Patterns

College of Integrated Traditional Chinese and Western Medicine，Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns，Hebei University of Chinese Medicine

School of Integrated Traditional Chinese and Western Medicine，Hebei University of Chinese Medicine，Hebei Provincial Key Laboratory of Integrated Traditional Chinese and Western Medicine Hepatorenal Syndrome

School of Basic Medicine，Changchun University of Chinese Medicine

Disciplinary Innovation Base of the Ministry of Education

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰